Your session is about to expire
← Back to Search
Drug Combinations for Colorectal Cancer
Study Summary
This trial is testing the safety and tolerability of different combinations of drugs in order to find the best doses and regimens for future studies.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I can and am willing to have a tumor biopsy before and during the study.I have or had lung inflammation not caused by an infection.I have another cancer, but it's either being treated or not life-threatening.My cancer has a BRAF V600 mutation.My cancer has worsened after 1 or 2 chemotherapy treatments, or I couldn't tolerate the treatment.I have a serious heart condition.I have a stomach or intestine problem that affects how I absorb medication.I have or am at risk for eye vein blockage or fluid build-up.My colon or rectum cancer cannot be surgically removed and has a specific mutation.
- Group 1: Dabrafenib + LTT462 + trametinib triplet arm 1
- Group 2: Dabrafenib + LTT462 + LXH254 triplet arm 2
- Group 3: Dabrafenib + LTT462 + Tislelizumab triplet arm 6
- Group 4: Dabrafenib + LTT462 backbone arm 1
- Group 5: Dabrafenib + trametinib + TNO155 triplet arm 5
- Group 6: Dabrafenib + LTT462 + spartalizumab triplet arm 4
- Group 7: Dabrafenib + LTT462 + TNO155 triplet arm 3
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What are the main aims of this research endeavor?
"This 30 month long trial is monitoring the frequency of dose interruptions, while also evaluating preliminary anti-tumor activity with Disease control rate (DCR) and Progression free survival (PFS). Additionally, AUClast derived from Serum/plasma concentration will be measured to better understand the pharmacokinetics of each drug."
What is the current status of Dabrafenib in terms of regulatory approval?
"As this is a preliminary Phase 1 medical trial, the safety of Dabrafenib has been rated a 1 due to its limited clinical data regarding effectiveness and security."
How many locations are presently conducting this trial?
"This trial is operating out of UCLA Medical Center Santa Monica Location in Los Angeles, California; Sarah Cannon Research Institute SC in Nashville, Tennessee; University of California at Los Angeles Santa Monica Location Boston, Massachusetts and 6 other sites."
Are there any related investigations that have been conducted utilizing Dabrafenib?
"The inaugural research on dabrafenib was conducted in 2011 by UCLA School of Medicine. There have been 115 concluded studies, with 118 more presently underway; the majority of these experiments are taking place in Los Angeles."
How many participants are currently involved in this research endeavor?
"To carry out the experiment, Novartis Pharmaceuticals needs to recruit 350 suitable candidates. As such, two participating medical centers have been identified - UCLA Medical Center Santa Monica Site in Los Angeles and Sarah Cannon Research Institute SC in Nashville."
Is enrollment for this examination still open?
"According to the official clinicaltrials.gov registry, this trial is actively recruiting applicants with a start date of July 22nd 2020 and an amended listing updated on June 7th 2022."
Is this an original clinical trial?
"Since 2011, Novartis Pharmaceuticals has sponsored research into dabrafenib. The initial investigation included 185 participants and the drug was successfully approved for Phase 1 in 2011. Presently, the medication is being assessed in 118 trials taking place across 1166 cities and 41 nations."
Share this study with friends
Copy Link
Messenger